Dec 10 (Reuters) - Astria Therapeutics ATXS.O:
ASTRIA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR STAR-0310, A MONOCLONAL ANTIBODY OX40 ANTAGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS
ASTRIA THERAPEUTICS INC: PHASE 1A TRIAL OF STAR-0310 IN HEALTHY VOLUNTEERS EXPECTED TO INITIATE IN Q1 2025
ASTRIA THERAPEUTICS INC: EARLY PROOF-OF-CONCEPT RESULTS EXPECTED IN Q3 2025
Source text: ID:nBw3gg0WFa
Further company coverage: ATXS.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。